Poxel's PXL065, a deuterium-stabilized R-enantiomer of pioglitazone, demonstrated significant benefits in preventing pathological myocardial remodeling in a mouse model of hypertrophic cardiomyopathy.
DelveInsight's 2025 report reveals a robust pipeline with 75+ companies developing 80+ therapies for chronic kidney disease, highlighting significant industry investment in addressing this growing health concern.
Multiple companies are developing novel therapies for Adrenoleukodystrophy (ALD), a rare genetic disorder affecting the adrenal glands and nervous system.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.